The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies

Clinical trial NCT04184414 · UNKNOWN

Trial details

NCT number: NCT04184414
Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Status: UNKNOWN
Phase: Early Phase 1
Study type: INTERVENTIONAL

B Acute Lymphoblastic Leukemia Mantle Cell Lymphoma Follicular Lymphoma

Start date: 2018-01-09
Primary completion: 2020-01-01
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.